Rebate Game Played By PBMs And Drug Makers Limits Biosimilar Competition
The rebate game played by drug makers and pharmacy benefit managers limits optimal biosimilar competition. As a result, U.S. patient out-of-pocket costs are too high.
The rebate game played by drug makers and pharmacy benefit managers limits optimal biosimilar competition. As a result, U.S. patient out-of-pocket costs are too high.
What's Your Reaction?
